- Policy
- President Moon said, "WHO selects Korea as a vaccine hub"
- by Kang, Shin-Kook Feb 28, 2022 05:54am
- President Moon Jae In evaluated that the government's efforts to become a vaccine hub country have paid off, saying that Korea has been exclusively selected as the "WHO Global Bio Human Resources Development Hub." President Moon posted on SNS on the 24th and said, "This is the result of being internationally recognized for Korea's biopharm
- Company
- Moderna and BeiGene joined KRPIA
- by Eo, Yun-Ho Feb 25, 2022 05:57am
- According to related industries, U.S.-Moderna Korea and Chinese-BeiGene Korea recently joined as KRPIA members. As a result, the number of KRPIA member companies has increased to 46. Both Moderna and BeiGene are multinational pharmaceutical companies that established a Korean subsidiary last year, and promotional activities are expected to
- Policy
- Voluntary price cuts of originals as ‘trade-offs’ an issue
- by Lee, Tak-Sun Feb 25, 2022 05:57am
- ‘Discounting the price of existing drugs to list high-priced new drugs.’ Recently, the pharmaceutical industry has been buzzing with speculations that some companies are voluntarily reducing the price of their original drugs as a fiscal sharing strategy to receive reimbursement. This strategy, which was considered unimaginable before
- Policy
- JW’s ‘Actemra’ reviewed for reimbursement as COVID-19 Tx
- by Lee, Tak-Sun Feb 25, 2022 05:57am
- The government is reviewing providing nsurance benefits to JW Pharmaceutical’s rheumatoid arthritis treatment ‘Actemra’ (tocilizumab)’ for the treatment of COVID-19. This is because the drug, which is being often used in Korea off-label to treat patients with severe COVID-19, is increasing patient burden due to its non-reimbursed co
- Company
- Shionogi COVID tx developed by Ildong has been approved
- by Kim, Jin-Gu Feb 25, 2022 05:56am
- Ildong Pharmaceutical announced on the 23rd that it has been approved by the MFDS to change the clinical trial plan of Shionogi's oral COVID-19 treatment candidate "S-217622" under development in Korea. &8203; Earlier, Ildong Pharmaceutical applied to change its clinical plan in the direction of confirming the results of each phase by modi
- Policy
- Pfizer COVID-19 vaccine for children has been approved
- by Lee, Hye-Kyung Feb 25, 2022 05:56am
- Pfizer's COVID-19 vaccine "Cominatiju 0.1mg/mL," which is subject to vaccination for children and adolescents aged 5 to 11, has obtained an item license. The MFDS (Minister Kim Kang-rip) announced on the 23rd that Pfizer Pharmaceutical Korea has approved "Comirati 0.1mg/mL" applied for permission as an imported item. Depending on the desig
- Policy
- Enactment of the Digital Healthcare Act begins in earnest
- by Lee, Jeong-Hwan Feb 24, 2022 05:59am
- With the National Assembly moving to enact a law specifically for the digital healthcare industry, attention is focused on whether the non-face-to-face treatment and drug delivery platform may gain momentum and make growth. The non-face-to-face and drug delivery platforms have been operating based on the non-face-to-face treatment that w
- Policy
- Phase 3 of SK Biopharm's Cenobamate is approved
- by Lee, Hye-Kyung Feb 24, 2022 05:58am
- Clinical trials have been approved at six hospitals, including Seoul National University, for children with partial epilepsy attacks. SK Biopharm will enter phase 3 of clinical trials for pediatric test takers of Xcopri (Cenobamate), a treatment for epilepsy. On the 23rd, the MFDS approved a phase 3 clinical trial plan for Cenobamate (YKP3
- Company
- Yuhan’s ‘Leclaza’ makes ₩4.1 billion in 6 months
- by Chon, Seung-Hyun Feb 24, 2022 05:58am
- Yuhan Corporation's new drug ‘Leclaza’ has made &8361;4.1 billion in its first year of release. In only 6 months since its sales began in earnest with reimbursement listing in July, Leclaza rose to the top among homegrown anticancer drugs, raising expectations on its potential for commercial success. According to the pharmaceutical rese
- Policy
- Generic for Revlimid was listed as the lowest price
- by Lee, Tak-Sun Feb 24, 2022 05:58am
- Boryung Pharmaceutical is launching a generic drug called Revlimid (Renalidomide) for multiple myeloma treatment after four years of approval. With three general companies targeting the market since 2018, Boryung has thrown a winning move at the lowest price. According to the contents of the "Partial revision of the drug benefit list and u
